Latest Repros Therapeutics Inc. Stories
NEW YORK, Oct.
NEW YORK, Sept. 29, 2014 /PRNewswire-USNewswire/ -- Androxal((R)) Second Pivotal Study from Repros Therapeutics Inc.
Repros Therapeutics Inc. (NasdaqGM:RPRX) announced today that it has filed a Form S-3 shelf registration statement with the Securities and Exchange Commission for up to 6,282,052 shares of common stock. The Company has filed this shelf registration statement for two reasons.
Repros Therapeutics Inc. (NasdaqGM:RPRX) announced today that the Company's President and CEO, Joseph Podolski, will present a corporate overview on Monday, November 3, 2008, at 2:00 p.m. Eastern Time during the Oppenheimer 19th Annual Healthcare Conference. Mr.
Repros Therapeutics Inc. (NasdaqGM:RPRX) today announces that it has consummated its previously announced sale of an aggregate of 2.4 million shares of its common stock resulting in net proceeds to the Company of approximately $15.5 million after deduction of estimated offering expenses.
- A serpent whose bite was fabled to produce intense thirst.